The genetic toxicity of methylphenidate: A review of the current literature

Journal of Applied Toxicology

Volumn 32, Issue 10, 2012, Pages 756-764

  Morris, Suzanne M ^a   Petibone, Dayton M ^a   Lin, Wei Jiun ^a   Chen, James J ^a   Vitiello, Benedetto ^b   Witt, Kristine L ^c   Mattison, Donald R ^d  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

ADHD; Chromosome damage; Methylphenidate; Mutation

Indexed keywords

METHYLPHENIDATE; PHENOBARBITAL;

ATTENTION DEFICIT DISORDER; CANCER INCIDENCE; CANCER RISK; CHROMOSOME PAINTING; COMET ASSAY; DNA DAMAGE; DOSE RESPONSE; DOUBLE STRANDED DNA BREAK; DRUG SAFETY; FLOW CYTOMETRY; FOOD AND DRUG ADMINISTRATION; GENE FREQUENCY; GENE MUTATION; GENETIC DAMAGE; GENOTOXICITY; HUMAN; MICRONUCLEUS TEST; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT DURATION;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOPAMINE UPTAKE INHIBITORS; HUMANS; METHYLPHENIDATE; MUTAGENICITY TESTS; RECEPTORS, DOPAMINE D1;

ANIMALIA;

EID: 84865809003     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2721     Document Type: Review

References (47)

1. Aguiar A, Eubig PA, Schantz SL. 2010. Attention deficit/hyperactivity disorder: a focused overview for children's environmental health researchers. Environ. Health Perspect. 118(12): 1646-1653.
2. American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorders (4th edn, text rev.). APA: Washington, DC.
3. Andreazza AC, Frey BN, Valvassoroi SS, Zanotto C, Gomes KM, Comim CM, Cassini C, Stertz L, Riberio LC, Quevedo J, Kapczinski F, Berk M, Goncalves CA. 2007. DNA damage in rats after treatment with methylphenidate. Prog. Neuropsychopharmacol. Biol. Psychiat. 31(6): 1282-1288.
4. Bagnyukova TV, Powell CL, Pavliv O, Tryndyak VP, Pogribny IP. 2008. Induction of oxidative stress and DNA damage in rat brain by a folate/methyl-deficient diet. Brain Res. 1237: 44-51.
5. Bartl J, Link P, Schlosser C, Gerlach M, Schmitt A, Walitza S, Riederer P, Grunblatt E. 2010. Effects of methylphenidate: the cellular point of view. Attent. Defic. Hyperact. Disord. 2(4): 225-232.
6. Bonassi S, Znaor A, Norppa H, Hagmar L. 2004. Chromosomal aberrations and risk of cancer in humans: an epidemiologic perspective. Cytogenet. Genome Res. 104(1-4): 376-382.
7. Bonassi S, Norppa H, Ceppi M, Stromberg U, Vermeulen R, Znaor A, Cebulska-Wasilewska A, Fabianova E, Fucic A, Gundy S, Hansteen IL, Knudsen LE, Rossner P, Sram RJ, Boffetta P. 2008. Chromosomal aberration frequency in lymphocytes predicts the risk of cancer: results from a pooled cohort study of 22 358 subjects in 11 countries. Carcinogenesis 29(6): 1178-1183.
8. Chovanova Z, Muchova J, Sivonova M, Dvorakova M, Zitnanova I, Waczulikova I, Trebaticka J, Skodacek I, Durackova Z. 2006. Effect of polyphenolic extract, Pycnogenol, on the level of 8-oxoguanine in children suffering from attention deficit/hyperactivity disorder. Free. Radic. Res. 40(9): 1003-1010.
9. Dobrovolsky VN, Shaddock JG, Mittelstaedt RA, Manjanatha MG, Miura D, Uchikawa M, Mattison DR, Morris SM. 2009. Evaluation of Macaca mulatta as a model for genotoxicity studies. Mutat. Res. 673(1): 21-28.
10. Dobrovolsky VN, Boctor SY, Twaddle NC, Doerge DR, Bishop ME, Manjanatha MG, Kimoto T, Miura D, Heflich RH, Ferguson SA. 2010. Flow cytometric detection of Pig-A mutant red blood cells using an erythroid-specific antibody: application of the method for evaluating the in vivo genotoxicity of methylphenidate in adolescent rats. Environ. Mol. Mutagen. 51(2): 138-145.
11. Dunnick JK, Hailey JR. 1995. Experimental studies on the long-term effects of methylphenidate hydrochloride. Toxicology 103(2): 77-84.
12. El-Zein RA, Abdel-Rahman SZ, Hay MJ, Lopez MS, Bondy ML, Morris DL, Legator MS. 2005. Cytogenetic effects in children treated with methylphenidate. Cancer Lett. 230(2): 284-291.
13. Faraone SV, Sergeant J, Gillberg C, Biederman J. 2003. The worldwide prevalence of ADHD: is it an American condition? Wld Psychiat. 2(2): 104-113.
14. Galloway SM, Armstrong MJ, Reuben C, Colman S, Brown B, Cannon C, Bloom AD, Nakamura F, Ahmed M, Duk S et al. 1987. Chromosome aberrations and sister chromatid exchanges in Chinese hamster ovary cells: evaluations of 108 chemicals. Environ. Mol. Mutagen. 10(suppl. 10): 1-175.
15. Gomes KM, Petronilho FC, Mantovani M, Garbelotto T, Boeck CR, Dal-Pizzol F, Quevedo J. 2008. Antioxidant enzyme activities following acute or chronic methylphenidate treatment in young rats. Neurochem. Res. 33(6): 1024-1027.
16. Hannestad J, Gallezot JD, Planeta-Wilson B, Lin SF, Williams WA, van Dyck CH, Malison RT, Carson RE, Ding YS. 2010. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol. Psychiat. 68(9): 854-860.
17. Jacobson-Kram D, Mattison D, Shelby M, Slikker W, Tice R, Witt K. 2008. Methylphenidate and chromosome damage. Cancer Lett. 260(1-2): 216-218.
18. -/- mice. Oncogene 25(17): 2425-2432.
19. Liu D, Croteau DL, Souza-Pinto N, Pitta M, Tian J, Wu C, Jiang H, Mustafa K, Keijzers G, Bohr VA, Mattson MP. 2011. Evidence that OGG1 glycosylase protects neurons against oxidative DNA damage and cell death under ischemic conditions. J. Cereb. Blood Flow Metab. 31(2): 680-692.
20. Manjanatha MG, Shelton SD, Dobrovolsky VN, Shaddock JG, McGarrity LG, Doerge DR, Twaddle NW, Lin CJ, Chen JJ, Mattison DR, Morris SM. 2008. Pharmacokinetics, dose-range, and mutagenicity studies of methylphenidate hydrochloride in B6C3F1 mice. Environ. Mol. Mutagen. 49(8): 585-593.
21. Manjanatha MG, Shelton SD, Dobrovolsky VN, Shaddock JG, McGarrity LG, Twaddle NW, Moore MM, Mattison DR, Slikker W Jr, Morris SM. 2009. Evaluation of mutagenic mode of action in Big Blue mice fed methylphenidate for 24 weeks. Mutat. Res. 680(1-2): 43-48.
22. Martins MR, Reinke A, Petronilho FC, Gomes KM, Dal-Pizzol F, Quevedo J. 2006. Methylphenidate treatment induces oxidative stress in young rat brain. Brain Res. 1078(1): 189-197.
23. Morris SM, Dobrovolsky VN, Shaddock JG, Mittelstaedt RA, Bishop ME, Manjanatha MG, Shelton SD, Doerge DR, Twaddle NC, Chen JJ, Lin CJ, Paule MG, Slikker W, Hotchkiss CE, Petibone D, Tucker JD, Mattison DR. 2009. The genetic toxicology of methylphenidate hydrochloride in non-human primates. Mutat. Res. 673(1): 59-66.
24. Mortelmans K, Haworth S, Lawlor T, Speck W, Tainer B, Zeiger E. 1986. Salmonella mutagenicity tests: II. Results from the testing of 270 chemicals. Environ. Mutagen. 8(suppl. 7): 1-119.
25. National Toxicology Program. 1995. NTP toxicology and carcinogenesis studies of methylphenidate hydrochloride (CAS no. 298-59-9) in F344/N rats and B6C3F1 mice (feed studies). Natl. Toxicol. Program Tech. Rep. Ser. 439: 1-299.
26. Oestreicher N, Friedman GD, Jiang SF, Chan J, Quesenberry C Jr, Habel LA. 2007. Methylphenidate use in children and risk of cancer at 18 sites: results of surveillance analyses. Pharmacoepidemiol. Drug Saf. 16(12): 1268-1272.
27. Peters S, Portengen L, Bonassi S, Sram R, Vermeulen R. 2011. Intra- and interindividual variability in lymphocyte chromosomal aberrations: implications for cancer risk assessment. Am. J. Epidemiol. 174(4): 490-493.
28. Pinkel D, Thompson LH, Gray JW, Vanderlaan M. 1985. Measurement of sister chromatid exchanges at very low bromodeoxyuridine substitution levels using a monoclonal antibody in Chinese hamster ovary cells. Cancer Res. 45(11 Pt 2): 5795-5798.
29. Ponsa I, Ramos-Quiroga JA, Ribases M, Bosch R, Bielsa A, Ordeig MT, Morell M, Miro R, de Cid R, Estivill X, Casas M, Bayes M, Cormand B, Hervas A. 2009. Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate. Mutat. Res. 666(1-2): 44-49.
30. Preston RJ, Kollins SH, Swanson JM, Greenhill LL, Wigal T, Elliott GR, Vitiello B. 2005. Comments on 'Cytogenetic effects in children treated with methylphenidate' by El-Zein et al. Cancer Lett. 230(2): 292-294.
31. Schmidt AJ, Clement HW, Gebhardt S, Hemmeter UM, Schulz E, Krieg JC, Kircher T, Heiser P. 2010a. Impact of psychostimulants and atomoxetine on the expression of 8-hydroxyguanine glycosylase 1 in human cells. J. Neural Transm. 117(6): 793-797.
32. Schmidt AJ, Krieg JC, Clement HW, Gebhardt S, Schulz E, Heiser P. 2010b. Impact of drugs approved for treating ADHD on the cell survival and energy metabolism: an in-vitro study in human neuronal and immune cells. J. Psychopharmacol. 24(12): 1829-1833.
33. Singh VK, Ganesh L, Cunningham ML, Shane BS. 2001. Comparison of the mutant frequencies and mutation spectra of three non-genotoxic carcinogens, oxazepam, phenobarbital, and Wyeth 14, 643, at the lambdacII locus in Big Blue transgenic mice. Biochem. Pharmacol. 62(6): 685-692.
34. Spencer TJ, Biederman J, Ciccone PE, Madras BK, Dougherty DD, Bonab AA, Livni E, Parasrampuria DA, Fischman AJ. 2006. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am. J. Psychiat. 163(3): 387-395.
35. +/- hemizygous knockout mouse: overview of available data. Toxicol. Pathol. 29(suppl): 30-50.
36. Suter W, Martus HJ, Elhajouji A. 2006. Methylphenidate is not clastogenic in cultured human lymphocytes and in the mouse bone-marrow micronucleus test. Mutat. Res. 607(2): 153-159.
37. Teo SK, San RH, Wagner VO, Gudi R, Stirling DI, Thomas SD, Khetani VD. 2003. d-Methylphenidate is non-genotoxic in in vitro and in vivo assays. Mutat. Res. 537(1): 67-79.
38. Tripp G, Wickens JR. 2009. Neurobiology of ADHD. Neuropharmacology 57(7-8): 579-589.
39. Tucker JD, Christensen ML, Strout CL, Carrano AV. 1986. Determination of the baseline sister chromatid exchange frequency in human and mouse peripheral lymphocytes using monoclonal antibodies and very low doses of bromodeoxyuridine. Cytogenet. Cell Genet. 43(1-2): 38-42.
40. Tucker JD, Suter W, Petibone DM, Thomas RA, Bailey NL, Zhou Y, Zhao Y, Muniz R, Kumar V. 2009. Cytogenetic assessment of methylphenidate treatment in pediatric patients treated for attention deficit hyperactivity disorder. Mutat. Res. 677(1-2): 53-58.
41. Walitza S, Werner B, Romanos M, Warnke A, Gerlach M, Stopper H. 2007. Does methylphenidate cause a cytogenetic effect in children with attention deficit hyperactivity disorder? Environ. Health Perspect. 115(6): 936-940.
42. Walitza S, Kampf K, Artamonov N, Romanos M, Gnana Oli R, Wirth S, Warnke A, Gerlach M, Stopper H. 2009. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy. Toxicol. Lett. 184(1): 38-43.
43. Walitza S, Kampf K, Oli RG, Warnke A, Gerlach M, Stopper H. 2010. Prospective follow-up studies found no chromosomal mutagenicity of methylphenidate therapy in ADHD affected children. Toxicol. Lett. 193(1): 4-8.
44. Witt KL, Shelby MD, Itchon-Ramos N, Faircloth M, Kissling GE, Chrisman AK, Ravi H, Murli H, Mattison DR, Kollins SH. 2008. Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD. J. Am. Acad. Child Adolesc. Psychiat. 47(12): 1375-1383.
45. Witt KL, Malarkey DE, Hobbs CA, Davis JP, Kissling GE, Caspary W, Travlos G, Recio L. 2010. No increases in biomarkers of genetic damage or pathological changes in heart and brain tissues in male rats administered methylphenidate hydrochloride (Ritalin) for 28 days. Environ. Mol. Mutagen. 51(1): 80-88.
46. Wong AW, McCallum GP, Jeng W, Wells PG. 2008. Oxoguanine glycosylase 1 protects against methamphetamine-enhanced fetal brain oxidative DNA damage and neurodevelopmental deficits. J. Neurosci. 28(36): 9047-9054.
47. Zuvekas SH, Vitiello B. 2011. Stimulant medication use among U.S. children: a twelve-year perspective. (E-pub ahead of print) Am. J. Psychiat. doi: 10.1176/appi.ajp.2011.11030387